File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration

TitleModelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration
Authors
KeywordsResistance
Mathematical modeling
Hepatitis C virus
Pharmacokinetics/pharmacodynamics
Issue Date2014
Citation
Journal of Antimicrobial Chemotherapy, 2014, v. 69, n. 3, p. 724-727 How to Cite?
AbstractObjectives: Daclatasvir is a highly potent inhibitor of hepatitis C virus. We estimated the active tissue concentration of daclatasvir in vivo. Methods: We developed a mathematical model incorporating pharmacokinetic/pharmacodynamic and viral dynamics. By fitting the model to clinical data reported previously, we estimated the ratio between plasma drug concentration and active tissue concentration in vivo. Results: The modelling results show that the active tissue concentration of daclatasvir is ~9% of the concentration measured in plasma (95% CI 1%=29%). Conclusions: Using plasma concentrations as surrogates for clinical recommendations may lead to substantial underestimation of the risk of resistance. © The Author 2013. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/285723
ISSN
2023 Impact Factor: 3.9
2023 SCImago Journal Rankings: 1.271
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKe, Ruian-
dc.contributor.authorLoverdo, Claude-
dc.contributor.authorQi, Hangfei-
dc.contributor.authorOlson, C. Anders-
dc.contributor.authorWu, Nicholas C.-
dc.contributor.authorSun, Ren-
dc.contributor.authorLloyd-smith, James O.-
dc.date.accessioned2020-08-18T04:56:28Z-
dc.date.available2020-08-18T04:56:28Z-
dc.date.issued2014-
dc.identifier.citationJournal of Antimicrobial Chemotherapy, 2014, v. 69, n. 3, p. 724-727-
dc.identifier.issn0305-7453-
dc.identifier.urihttp://hdl.handle.net/10722/285723-
dc.description.abstractObjectives: Daclatasvir is a highly potent inhibitor of hepatitis C virus. We estimated the active tissue concentration of daclatasvir in vivo. Methods: We developed a mathematical model incorporating pharmacokinetic/pharmacodynamic and viral dynamics. By fitting the model to clinical data reported previously, we estimated the ratio between plasma drug concentration and active tissue concentration in vivo. Results: The modelling results show that the active tissue concentration of daclatasvir is ~9% of the concentration measured in plasma (95% CI 1%=29%). Conclusions: Using plasma concentrations as surrogates for clinical recommendations may lead to substantial underestimation of the risk of resistance. © The Author 2013. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.-
dc.languageeng-
dc.relation.ispartofJournal of Antimicrobial Chemotherapy-
dc.subjectResistance-
dc.subjectMathematical modeling-
dc.subjectHepatitis C virus-
dc.subjectPharmacokinetics/pharmacodynamics-
dc.titleModelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1093/jac/dkt423-
dc.identifier.pmid24169581-
dc.identifier.pmcidPMC3922152-
dc.identifier.scopuseid_2-s2.0-84894048352-
dc.identifier.volume69-
dc.identifier.issue3-
dc.identifier.spage724-
dc.identifier.epage727-
dc.identifier.eissn1460-2091-
dc.identifier.isiWOS:000331827200021-
dc.identifier.issnl0305-7453-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats